ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Bayer To Develop Cancer Treatment With Amgen

FRANKFURT -(Dow Jones)- German chemical and pharmaceutical company Bayer AG (BAYN.XE) said Tuesday it has agreed with Amgen Inc. (AMGN) to develop and commercialize a new antibody for treating cancer. MAIN FACTS: -Financial details of the deal weren't disclosed. -Bayer will collaborate with Amgen at its Munich site from the research phase to the completion of initial clinical trials. -After the initial trials have been completed, Bayer will be responsible for further development and commercialization of the product candidate. -In 2009, Bayer had entered into an agreement with Micromet, Inc. to produce another antibody. -Micromet was acquired by Amgen in early 2012. -Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
04/27/201513:03:02Biotech Bubble Bursting? 3 Stocks I Want to Buy
04/27/201512:09:37The Internet of Things is About to Solve Biotech's Oldest Problem
04/27/201511:23:53The Internet of Things is About to Solve Biotech's Oldest Problem
04/27/201511:00:02The Internet of Things is About to Solve Biotech's Oldest Problem
04/25/201507:06:02Are Biosimilars the Next Big Thing in Biotech?
04/24/201516:54:55Statement of Changes in Beneficial Ownership (4)
04/24/201510:02:02Illumina's Earnings Set Positive Tone for Biotech
04/23/201517:31:15Confidential Treatment Order (ct Order)
04/23/201517:06:07Statement of Changes in Beneficial Ownership (4)
04/23/201517:02:33Nasdaq Composite Closes at Record High
04/23/201515:47:20Nasdaq Composite Rises Above March 2000 Record Close
04/23/201514:44:46AbbVie Profit Rises on Broad Sales Growth -- Update
04/23/201513:29:06Amgen, Inc. Earnings: 4 Things You Probably Overlooked
04/23/201512:03:02Is Amgen Inc.'s Dividend Sustainable?
04/23/201505:10:21Barclays Reiterates "Equal Weight" Rating for Amgen (AMGN)
04/22/201517:04:58Additional Proxy Soliciting Materials (definitive) (defa14a)
04/22/201517:00:39Additional Proxy Soliciting Materials (definitive) (defa14a)
04/22/201510:49:40Amgen Price Target Raised to $195.00 (AMGN)
04/22/201510:12:19Nomura Cuts Amgen Price Target to $191.00 (AMGN)
04/22/201504:35:02Amgen PT Raised to $187.00 at Leerink Swann (AMGN)

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad